Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™

ConditionCoagulation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorPerosphere Technologies Inc.

About this trial

The Perosphere ClotChek™ system consists of a hand-held, battery-operated blood coagulation instrument and disposable test cuvettes for use at the point-of-care (POC). The instrument performs a whole blood clotting time (WBCT) test using freshly drawn, non-citrated whole blood. The purpose of the present study is to characterize the performance of the Perosphere ClotChek™ as a quantitative measurement of the WBCT in patients taking one of the following Direct Oral Anticoagulants (DOACs), rivaroxaban or apixaban.

Eligibility criteria

Qualifiers

Be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed.

Be 18- to 80-years-of-age, inclusive, at time of consent.

Have suitable venous access for at least a single venipuncture.

Eligible patients on anticoagulants must have taken their prescribed anticoagulant regularly at least for one month prior to study participation for inclusion

Disqualifiers

Have a personal or family history of clotting disorder or hematologic abnormality, such as excessive bleeding, joint hematoma, thrombovascular disease, thrombocytopenia, or any chronic condition requiring treatment with transfusions, other than the condition for which a DOAC was prescribed.

Have a history of unexplained syncope.

Have a history within six months prior to Screening of peptic ulcer or gastrointestinal bleeding (including hematemesis, melena, or rectal bleeding).

Consume more than five cigarettes per day.

Trial design

Treatments tested in this trial

  • Whole Blood Clotting Time
  • Whole Blood Clotting Time

Treatment groups

No treatment groups listed

Sponsors and collaborators